Retrophin, Inc. (NASDAQ:RTRX) today reported its financial results for the quarter ended March 31, 2014.
“The first quarter of 2014 was a transformative period for Retrophin,” said Martin Shkreli, Founder and Chief Executive Officer of Retrophin. “We listed our stock on the NASDAQ and completed a successful public offering in January. In March, we acquired Manchester Pharmaceuticals and became a commercial company with two FDA-approved products.
Help employers find you! Check out all the jobs and post your resume.
